CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Core Insights - CervoMed Inc. is participating in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, in New York, NY [1][2] - The company is focused on developing treatments for age-related neurologic disorders, specifically through its investigational drug neflamapimod [3] Company Overview - CervoMed is a clinical-stage company targeting age-related neurologic disorders [3] - The company is developing neflamapimod, an orally administered small molecule that inhibits p38 mitogen-activated protein kinase alpha [3] - Neflamapimod aims to address synaptic dysfunction associated with neurodegenerative diseases, including Dementia with Lewy Bodies (DLB) [3] - A recent Phase 2b trial of neflamapimod was completed, focusing on patients with DLB [3]